Merck 2008 Annual Report Download - page 37

Download and view the complete annual report

Please find page 37 of the 2008 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 153

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153

32 | Merck Annual Report 2008
Merck Serono
Merck Serono is the largest division of Merck. It focuses on specialist therapeutic
areas and markets innovative prescription drugs of chemical and biotechnological
origin, including monoclonal antibodies and other therapeutic proteins, in more
than 150 countries.
Key therapeutic areas/products
– Oncology: Erbitux® (solid tumors)
– Neurodegenerative Diseases: Rebif® (multiple sclerosis)
– Autoimmune and Inflammatory Diseases: Raptiva® (psoriasis)
– Fertility: Gonal-f®, Pergoveris™, Luveris®, Ovitrelle®, Crinone®, Cetrotide® (infertility)
– Endocrinology: Saizen® (growth hormone disorders),
Serostim® (HIV-associated wasting)
– CardioMetabolic Care: Glucophage® family (type 2 diabetes),
Concor® family (cardiovascular diseases), Euthyrox® (thyroid disorders)
Key events in 2008
– Return on sales (ROS) rises from 8.0% to 11.9%
– Approvals of Erbitux® in the EU for first-line treatment of head and neck tumors
and metastatic colorectal cancer (KRAS wild-type) and in Japan for the treatment
of metastatic colorectal cancer after the failure of irinotecan
– Groundbreaking ceremony for the expansion of the production site in Corsier-sur-
Vevey (Switzerland) to manufacture biological therapies
– Approval of Kuvan® in the EU for the treatment of hyperphenylalaninemia resulting
from phenylketonuria or BH4 deficiency